Dashboard
Manage Tickers

LPCNLipocine Inc.

Nasdaq lipocine.com


$ 3.70 $ 0.00 (0 %)    

Monday, 19-Aug-2024 12:24:19 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 478.69 $ 3.03 (0.64 %)
DIA $ 408.31 $ 0.88 (0.22 %)
SPY $ 557.80 $ 2.91 (0.52 %)
TLT $ 97.95 $ 0.01 (0.01 %)
GLD $ 231.46 $ 1.26 (0.55 %)
$ 3.7
$ 3.63
$ 3.76 x 100
$ 3.83 x 100
$ 3.60 - $ 3.70
$ 2.31 - $ 11.79
45,093
na
19.77M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-07-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-10-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-09-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-11-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-13-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 03-06-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-07-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-08-2017 03-31-2017 10-Q
31 03-06-2017 12-31-2016 10-K
32 11-08-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-10-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-11-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 03-11-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lipocine-q2-2024-gaap-eps-056-beats-078-estimate-sales-89565k-miss-290000k-estimate
Lipocine Q2 2024 GAAP EPS $(0.56) Beats $(...
08/08/2024 10:30:39

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.78) by 2...

lipocine-says-lpcn-1154-met-standard-bioequivalence-be-criteria-co-says-on-track-for-nda-filing-targeting-q4-2024
Lipocine Says LPCN 1154 Met standard Bioeq...
06/25/2024 12:06:15

Met standard bioequivalence (BE) criteria Cmax, AUC0-t, and AUC0-∞Ctrough criterion was metLPCN 1154 was well tolerated with no...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
06/19/2024 16:30:59

lipocine-to-present-52-week-results-from-lpcn-1148-phase-2-study-in-late-breaking-session-at-easl-congress-2024
Lipocine To Present 52 Week Results From L...
06/10/2024 12:02:02

 Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were ...

lipocine-q1-eps-066-up-from-076-yoy-sales-750m-up-from-5499k-yoy
Lipocine Q1 EPS $0.66 Up From $(0.76) YoY,...
05/09/2024 13:08:40

Lipocine (NASDAQ:LPCN) reported quarterly earnings of $0.66 per share. This is a 186.84 percent increase over losses of $(0.76)...

lipocine-announces-late-breaking-oral-presentation-of-data-from-the-phase-2-study-of-lpcn-1148-at-easl-congress-2024
Lipocine Announces Late Breaking Oral Pres...
05/08/2024 12:04:28

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has bee...

lipocine-announces-completion-of-dosing-in-pivotal-study-of-postpartum-depression-candidate-lpcn-1154
Lipocine Announces Completion Of Dosing In...
05/01/2024 12:15:23

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
04/11/2024 12:10:58

lipocine-shares-are-trading-higher-after-the-company-announced-trial-data-showing-lpcn-2401-treatment-resulted-in-statistically-significant-body-composition-improvement-in-men
Lipocine shares are trading higher after t...
04/11/2024 11:21:49

lipocine-announced-results-from-a-phase-2-trial-of-lpcn-2401-showing-significant-improvement-in-body-composition-through-decreased-fat-mass-and-increased-lean-mass-or-fat-free-mass-in-obese-patients-with-at-least-one-weight-related-comorbidity
Lipocine Announced Results From A Phase 2 ...
04/11/2024 11:04:37

lipocine-announces-week-52-results-from-lpcn-1148-phase-2-study-in-patients-with-cirrhosis-says-met-primary-and-hepatic-encephalopathy-endpoints-in-phase-2-study
Lipocine Announces Week 52 Results From LP...
03/28/2024 12:02:19

lipocine-announces-first-cohort-dosed-in-pivotal-study-of-lpcn-1154
Lipocine Announces First Cohort Dosed in P...
03/25/2024 12:02:36

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveragi...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
03/13/2024 21:32:47

lipocine-announces-confirmation-of-dosing-regimen-for-pivotal-study-of-lpcn-1154
Lipocine Announces Confirmation Of Dosing ...
02/06/2024 13:02:01

Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK studyOn track for Q2-24 pivotal study topline...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
01/18/2024 13:05:59

lipocine-and-verity-pharma-enter-into-license-agreement-for-tlando-franchise-in-the-us-and-canada-lipocine-to-receive-11m-license-fee-up-to-259m-in-development-and-commercial-sales-milestones
Lipocine And Verity Pharma Enter Into Lice...
01/18/2024 13:03:03

Lipocine to receive $11 million license feeUp to $259 million in development and commercial sales milestonesTiered royalties on...

lipocine-releases-late-breaking-presentation-on-lpcn-1148-phase-2-results-at-the-liver-meeting-2023
Lipocine Releases Late Breaking Presentati...
11/13/2023 19:46:19

Results demonstrate improvements in sarcopenia and other clinically meaningful outcomesPatients converting from placebo to LPCN...

lipocine-received-notice-from-antares-of-antares-termination-of-the-license-agreement-terms-say-the-license-agreement-will-terminate-effective-jan-31-2024
Lipocine Received Notice From Antares Of A...
10/06/2023 20:12:57

https://www.sec.gov/ix?doc=/Archives/edgar/data/1535955/000149315223036494/form8-k.htm

stocks-that-hit-52-week-lows-on-thursday
Stocks That Hit 52-Week Lows On Thursday
09/28/2023 18:32:08

  During Thursday's session, 406 companies made new 52-week lows.

watching-lipocine-inc-zacks-small-cap-research-sets-40-price-valuation
Watching Lipocine Inc.; Zacks Small-Cap Re...
08/16/2023 13:35:18

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_08162023_LPCN_Vandermosten.pdf

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION